Bridging the primary care gap: The role of in-house pharmacies in today’s healthcare marketplace

Holly Russo, Maxor 340B

SPONSORED CONTENT

Healthcare leaders have a lot on their plates. Today’s healthcare landscape requires health care organizations to compete in attracting and retaining qualified employees, remain up to date on reimbursement changes, select and employ technologies to serve more patients in convenient ways, and adhere to quality standards to serve their communities.

With

Read More »

Part 2 of 2: Understanding the Top Five Challenges Facing Health Center Pharmacies Today

Holly Russo headshot

SPONSORED CONTENT

Part 2 of 2: Navigating staffing shortages, unpredictable demand, and complex industry requirements

While in-house pharmacies offer a wide array of benefits both for the community health center (CHC) and their patient populations, overseeing the myriad of administrative, operational, financial, and regulatory intricacies can prove

Read More »

Part 1 of 2: Understanding the Top Five Challenges Facing Health Center Pharmacies Today

Holly Russo headshot

SPONSORED CONTENT

Part 1 of 2: Managing costs and ensuring favorable contracting

As industry veterans know too well, having an in-house pharmacy can be greatly beneficial for both community health centers (CHCs) and their patients. Not only do they offer patient convenience and a greater level

Read More »

10 Questions to Ask Your 340B TPA about Your Contract and Fees

Holly Russo, Maxor 340B

SPONSORED CONTENT

If you have one or more agreements with 340B Third Party Administrator(s) (TPA) to manage your contract pharmacy arrangements, how much do you know about those contracts and associated fees?  Chances are, you don’t know the answers to all the questions that follow.  Be sure to contact your 340B TPA(s) and ask:

    Read More »

    Covered Entities and the 340B Program: Avoid Common Pitfalls of the Medicaid Exclusion File

    Holly Russo headshot

    SPONSORED CONTENT

    When a covered entity enrolls in the 340B program it must inform the Health Resources and Services Administration (HRSA) whether it will “carve in” and acquire 340B drugs for its Medicaid fee-for-service (FFS) eligible patients, or “carve out” and purchase drugs for its FFS patients outside the 340B program.

    A covered entity choosing to

    Read More »
    Generic selectors
    Exact matches only
    Search in title
    Search in content
    Post Type Selectors
    ×

    *Sign up for news summaries and alerts from 340B Report